Q32 Bio Inc.
QTTBDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 2 past
QTTB Earnings Report
EPS Est: $-0.53 | FQ end 2026-06
How QTTB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
bempikibart (ADX-914) | Phase 2 | Alopecia Areata | - | - |
ADX-914 | Phase 2 | Atopic Dermatitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Q32 Bio Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Q32 Bio Inc.'s (QTTB) pipeline across Phase 2. Its lead program is bempikibart (ADX-914) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Q32 Bio Inc.'s next FDA catalyst?→
Q32 Bio Inc.'s (QTTB) next tracked catalyst is a Data Readout expected July 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QTTB biotech catalysts?→
Add QTTB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Q32 Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.